SLC5A2 and hydrops fetalis: The use of SGLT2Is was an independent predictor of reduced risk of MACE (aHR = 0.57; 95% CI 0.33–0.99; p = 0.039) and HF hospitalization (aHR = 0.46; 95% CI 0.21–0.98; p = 0.041). CIN: among SGLT2Is users 6/111, 70/535 among non-SGLT2-I users (p = 0.022). Crude RR 0.4131; 95% CI 0.1841-0.9271.